Company / CIK 0001178670
ALNYLAM PHARMACEUTICALS, INC.
- Ticker
- ALNY
- Size, estimated from filings
- Large cap ($10B – $200B)
- Insiders on file
- 10
- Members of Congress who traded it
- 1
- Federal contracts on record
- none matched
- Lobbying filings on record
- 29
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 2, 2026
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 10 insiders on file who disclosed 24 transactions in the last 12 months (0 open-market buys, 6 sales, about $1.5M at reported prices), and 1 congressional trade in its stock is on record. No federal contract award that started in the last 180 days was found for a recipient with exactly this name, and 15 lobbying filings naming it as client report $1.6M in 2026.
ALNYLAM PHARMACEUTICALS, INC. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
3 people account for the disclosed buying and selling in ALNYLAM PHARMACEUTICALS, INC. over the last 12 months; the most active is PYOTT DAVID E I with $1.1M.
Lobbying spend by quarter
How much has ALNYLAM PHARMACEUTICALS, INC. reported spending on federal lobbying?
ALNYLAM PHARMACEUTICALS, INC. reported $2.9M in lobbying over the last eight quarters, from filings matched by exact company name.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| SUPRAN BRYAN | EVP, CLO and Secretary | 1 | 0 | 1 | October 6, 2026 |
| Greenstreet Yvonne | Chief Executive Officer | 1 | 0 | 0 | September 22, 2026 |
| BRANDICOURT OLIVIER | Director | 2 | 0 | 0 | June 16, 2026 |
| PYOTT DAVID E I | Director | 9 | 0 | 5 | June 3, 2026 |
| Cravatt Benjamin | Director | 1 | 0 | 0 | June 3, 2026 |
| Sigal Charles Elliott | Director | 2 | 0 | 0 | May 22, 2026 |
| SCHULMAN AMY W | Director | 2 | 0 | 0 | May 22, 2026 |
| Reitan Colleen F | Director | 2 | 0 | 0 | May 22, 2026 |
| KELLOGG PETER N | Director | 2 | 0 | 0 | May 22, 2026 |
| HAMBURG MARGARET A | Director | 2 | 0 | 0 | May 22, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Members of Congress who traded ALNY
From periodic transaction reports that name the company's stock. Amounts are the sums of the ranges as filed. Every row is on the ALNY page.
| Member | Seat | Trades | Bought | Sold | Range as filed | Latest |
|---|---|---|---|---|---|---|
| Cory A. Booker | Senator (NJ), Democrat | 1 | 0 | 1 | $1,001–$15K | August 11, 2026 |
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPRAN BRYAN | ALNY | Sell S | October 2, 2026 | October 6, 2026 | 4d | 1,758 | $227 | $399K | Form 4 ↗ | ||
| Greenstreet Yvonne | ALNY | Other A | September 19, 2026 | September 22, 2026 | 3d | 107 | — | — | Form 4 ↗ | ||
| Cravatt Benjamin | ALNY | Other A | June 1, 2026 | June 3, 2026 | 2d | 4,393 | — | — | derivative | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Option / conversion M | June 1, 2026 | June 3, 2026 | 2d | 3,830 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Sell S | June 1, 2026 | June 3, 2026 | 2d | 17 | $303 | $5,145 | 10b5-1 plan | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Sell S | June 1, 2026 | June 3, 2026 | 2d | 495 | $301 | $149K | 10b5-1 plan | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Sell S | June 1, 2026 | June 3, 2026 | 2d | 1,222 | $300 | $366K | 10b5-1 plan | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Sell S | June 1, 2026 | June 3, 2026 | 2d | 1,175 | $299 | $351K | 10b5-1 plan | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Sell S | June 1, 2026 | June 3, 2026 | 2d | 921 | $298 | $274K | 10b5-1 plan | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Option / conversion M | June 1, 2026 | June 3, 2026 | 2d | 3,830 | — | — | 10b5-1 plan | Form 4 ↗ | |
| BRANDICOURT OLIVIER | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| BRANDICOURT OLIVIER | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ | ||
| HAMBURG MARGARET A | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| HAMBURG MARGARET A | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ | ||
| KELLOGG PETER N | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| KELLOGG PETER N | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ | ||
| PYOTT DAVID E I | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| PYOTT DAVID E I | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ | ||
| Reitan Colleen F | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| Reitan Colleen F | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ | ||
| SCHULMAN AMY W | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,802 | — | — | derivative | Form 4 ↗ | |
| SCHULMAN AMY W | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 838 | — | — | Form 4 ↗ | ||
| Sigal Charles Elliott | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,441 | — | — | derivative | Form 4 ↗ | |
| Sigal Charles Elliott | ALNY | Other A | May 20, 2026 | May 22, 2026 | 2d | 671 | — | — | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "ALNYLAM PHARMACEUTICALS, INC.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
| Period | Registrant | Primary issue | Amount | Source |
|---|---|---|---|---|
| 2026 Q3 | TODD STRATEGY GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q3 | LMH STRATEGIC SOLUTIONS | Medicare/Medicaid | $50,000 | LDA ↗ |
| 2026 Q3 | CAPITOL COUNSEL LLC | Medical/Disease Research/Clinical Labs | $30,000 | LDA ↗ |
| 2026 Q2 | ALNYLAM PHARMACEUTICALS, INC. | Pharmacy | $450,000 | LDA ↗ |
| 2026 Q2 | SPLITOAK STRATEGIES LLC | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q2 | TODD STRATEGY GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q2 | TIBER CREEK GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q2 | LMH STRATEGIC SOLUTIONS | Medicare/Medicaid | $50,000 | LDA ↗ |
| 2026 Q2 | CAPITOL COUNSEL LLC | Medical/Disease Research/Clinical Labs | $30,000 | LDA ↗ |
| 2026 Q1 | ALNYLAM PHARMACEUTICALS, INC. | Medicare/Medicaid | $430,000 | LDA ↗ |
| 2026 Q1 | TIBER CREEK GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q1 | TODD STRATEGY GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q1 | CAPITOL COUNSEL LLC | Medical/Disease Research/Clinical Labs | $60,000 | LDA ↗ |
| 2026 Q1 | SPLITOAK STRATEGIES LLC | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2026 Q1 | LMH STRATEGIC SOLUTIONS | Medicare/Medicaid | $50,000 | LDA ↗ |
| 2025 Q4 | ALNYLAM PHARMACEUTICALS, INC. | Pharmacy | $390,000 | LDA ↗ |
| 2025 Q4 | LMH STRATEGIC SOLUTIONS | Medicare/Medicaid | $70,000 | LDA ↗ |
| 2025 Q4 | SPLITOAK STRATEGIES LLC | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q4 | TODD STRATEGY GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q4 | TIBER CREEK GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q4 | CAPITOL COUNSEL LLC | Medical/Disease Research/Clinical Labs | $30,000 | LDA ↗ |
| 2025 Q3 | ALNYLAM PHARMACEUTICALS, INC. | Medicare/Medicaid | $390,000 | LDA ↗ |
| 2025 Q3 | LMH STRATEGIC SOLUTIONS | Medicare/Medicaid | $70,000 | LDA ↗ |
| 2025 Q3 | SPLITOAK STRATEGIES LLC | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q3 | TIBER CREEK GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q3 | TODD STRATEGY GROUP | Medicare/Medicaid | $60,000 | LDA ↗ |
| 2025 Q3 | CAPITOL COUNSEL LLC | Medical/Disease Research/Clinical Labs | $30,000 | LDA ↗ |
| 2025 Q3 | THE MCMANUS GROUP | Medicare/Medicaid | $20,000 | LDA ↗ |
| 2024 Q3 | SPLITOAK STRATEGIES LLC | Medicare/Medicaid | $60,000 | LDA ↗ |
Related companies
Companies whose stock was traded by the same people who traded ALNY, by number of filers in common. It shows overlap in public filings and nothing else.
- NETFLIX INC NFLX 1 filer in common
- NVIDIA CORP NVDA 1 filer in common
- AMAZON COM INC AMZN 1 filer in common
- MCDONALDS CORP MCD 1 filer in common
- Vaxcyte, Inc. PCVX 1 filer in common
- JD.com, Inc. JD 1 filer in common
- Elevance Health, Inc. ELV 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Lobbying disclosure reports Reports are due about 20 days after each quarter ends.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| Senate eFD, periodic transaction reports | 1 | 1 | September 9, 2026 | September 9, 2026 | Senate eFD search |
| SEC EDGAR, Form 4 | 11 | 24 | May 22, 2026 | October 6, 2026 | Form 4 list on EDGAR |
| Lobbying disclosure filings | 29 filings | — | — | — | LDA.gov search |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.